ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions
View by Date
  • Abstract Number: 1649

    Mycophenolate Mofetil and Cyclophosphamide Improve Health-Related Quality of Life in Patients with Systemic Sclerosis Who Participated in SLS II
  • Abstract Number: 1650

    Baseline Skin Score, Older Age and CD34-selection Influence the Outcome of Autologous Stem Cell Transplantation for Systemic Sclerosis – Results of a Prospective Non-interventional Study from the European Society for Blood & Marrow Transplantation (EBMT)
  • Abstract Number: 1651

    Multicenter Double-Blind, Proof-of-Concept, Randomized Placebo-Controlled Trial of Riociguat in Systemic Sclerosis-associated Digital Ulcers
  • Abstract Number: 1652

    Anticentromere Antibody Levels and Isotypes Associate with Disease Severity in Systemic Sclerosis
  • Abstract Number: 1653

    Efficacy and Safety of Romilkimab in Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-Blind, Placebo-Controlled, 24-week, Proof of Concept Study
  • Abstract Number: 1654

    Esophageal Dilation and Other Clinical Factors Associated with Pulmonary Function Decline in Patients with Systemic Sclerosis
  • Abstract Number: 1655

    Histologic Features Correlate with the Modified Rodnan Skin Score, Serum Inflammatory Markers, and Patient Reported Outcomes in Patients with Early, Diffuse Cutaneous Systemic Sclerosis
  • Abstract Number: 1656

    Health-Related Quality of Life in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Impact of Lung Function on Patient-Reported Outcomes in a Randomized Phase III Trial
  • Abstract Number: 1657

    Sarcopenia in Systemic Sclerosis
  • Abstract Number: 1658

    Impact of Visceral Involvement in the Characterization and Prognosis of Patients Without Skin Involvement Classified as Systemic Sclerosis (SSc) According to 2013 ACR/EULAR Criteria in a Large Single Cohort
  • Abstract Number: 1659

    Linaclotide for the Treatment of Gastrointestinal Symptoms in Systemic Sclerosis
  • Abstract Number: 1660

    Serial Sublingual Videomicroscopy in Systemic Sclerosis Clinic: Are the Microcirculation Measurements Correlated with Gastrointestinal Symptoms?
  • Abstract Number: 1661

    Circulating Cell Free DNA Released from Eosinophils Is a Practical Biomarker in Patients with Eosinophilic Granulomatosis with Polyangiitis
  • Abstract Number: 1662

    Does PR3-ANCA+ Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss)Really Exist?
  • Abstract Number: 1663

    Assessments of Quality of Life in Patients with Eosinophilic Granulomatosis with Polyangiitis
  • « Previous Page
  • 1
  • …
  • 111
  • 112
  • 113
  • 114
  • 115
  • …
  • 198
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology